Aesculape SRI

Aesculape SRI

International Equities – Health Theme

Art.9

"The healthcare sector stands out as a driver of growth, resilience, and opportunities"

Key Points

  • A thematic international equity fund targeting companies fully exposed to the healthcare sector, with a focus on innovative treatments and services.
  • Our strategy focuses on three key segments:
    • Diagnostics: Biological analyses and medical imaging providing tailored solutions for each patient.
    • Discovery: Biopharma and biotech driving revolutionary treatments.
    • Production & Distribution: Opportunities tied to the increasing complexity of production, with a focus on outsourcing and strong franchises.
  • The goal is to prioritize companies with strong competitive advantages, robust pricing power, and significant barriers to entry.

Inception date

12 July 2021

Legal status

UCITS V coordinated French law mutual fund

AMF classification

Global Equity

PEA eligible (France only)

No

Currency

EUR

ISIN Codes

FR00140032U2 (Aesculape IC),
FR00140089L1 (Aesculape ID),
FR00140072U8 (Aesculape IPC),
FR001400Q1D7 (Aesculape RC)

Cost

Refer to the Prospectus and the KID of each share available above in the Documents section.

Investment management company

Montpensier Arbevel

Custodian

Caceis Bank France

Valuation

Daily (Caceis Fund Administration)

Cut-off

Refer to the prospectus and contact the banking institution through which the order was placed.

Investment horizon

Greater than 5 years

Approved for distribution in

France, Luxembourg

Centralist

Caceis Bank

Transfert agent

Caceis Bank, Luxembourg branch

SFDR

9
The decision to invest takes into account all the characteristics, objectives, and risks of the UCITS as described in the regulatory documentation of the UCITS: prospectus, KID, pre-contractual SFDR document if applicable, which should be consulted before making any final investment decision. The figures mentioned relate to past years. Past performance is not a reliable indicator of future performance. The UCITS presents a risk of capital loss.

ISIN: FR00140032U2

VL

256.73€

03/10/2025

Risk Indicator - SRI

The risk indicator is based on the assumption that you hold the product for 5 years. The actual risk may be significantly different if you choose to exit before the recommended holding period, and you could receive less in return. You risk selling your product at a price that could significantly impact the amount you ultimately receive.

Documents

Risks

  • Risk of capital loss: The fund does not offer any performance or capital guarantee.
  • Risk related to discretionary management: The risk that the fund may not be invested in the best-performing stocks at all times.
  • Equity risk: Stock markets can experience significant fluctuations, even a sharp decline. Furthermore, the fund invests up to 25% of its net assets in small-cap stocks, which, due to their specific characteristics, may pose risks for investors.
  • Sector concentration risk: The risk of losses due to the portfolio’s concentration in the healthcare sector. If this sector declines, the fund’s net asset value may fall more quickly and sharply than the stock markets, and exhibit increased volatility.
  • Sustainability risk: The UCITS is exposed to the risk that an event or situation in the environmental, social, or governance field, if it occurs, may have a significant negative impact, either real or potential, on the value of the portfolio’s securities.
  • Currency risk: The risk that the fund’s net asset value may decline if exchange rates fluctuate, with exposure to currency risk potentially reaching 100% of the net assets.
  • Other risks: Liquidity risk, risk related to the use of derivative instruments, emerging markets investment risk, interest rate risk, credit risk, risk related to speculative securities, risk related to convertible bonds, counterparty risk.

The risks are detailed in the prospectus.

YTD

2.85%

5 years performance​

-

3.66%